GlassScriptPhysician profile
Soe Min Tun
NPI 1801279799
$10,018.49
in general payments reported to CMS, 2019-2025
63 companies · $2,236 in 2025
The $2,236 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $411 · 2022: $1,810 · 2023: $3,123 · 2024: $2,438 · 2025: $2,236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,980 · Education: $816.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,980.43 |
| Education | $816.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $851.36 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $805.53 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $586.25 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Daiichi Sankyo INC. | $560.84 | 2021-2025 | Enhertu |
| E.R. Squibb & Sons, L.L.C. | $497.22 | 2021-2025 | Opdivo, Opdualag, Krazati |
| Janssen Biotech, INC. | $494.27 | 2021-2025 | Darzalex, Rybrevant, Talvey |
| Seagen INC. | $412.92 | 2021-2023 | Padcev, Tukysa, Adcetris |
| Astellas Pharma US INC | $410.21 | 2021-2025 | Vyloy, Xospata, Padcev |
| Eisai INC. | $392.94 | 2022-2025 | |
| Abbvie INC. | $391.44 | 2021-2025 | Venclexta |
| Lilly USA, LLC | $282.51 | 2021-2025 | Verzenio, Jaypirca, Retevmo |
| Exelixis INC. | $239.58 | 2022-2025 | Cabometyx |
| Celgene Corporation | $235.38 | 2022-2025 | Reblozyl, Pomalyst, Opdualag |
| Incyte Corporation | $233.46 | 2022-2025 | Jakafi, Niktimvo, Pemazyre |
| Takeda Pharmaceuticals U.S.A., INC. | $205.54 | 2021-2025 | Iclusig, Ninlaro, Fruzaqla |
Show all 63 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $202.76 | 2022-2023 | Imbruvica |
| Karyopharm Therapeutics INC. | $193.03 | 2021-2025 | Xpovio |
| Tersera Therapeutics LLC | $187.27 | 2022-2025 | Zoladex |
| Amgen INC. | $184.18 | 2021-2023 | Kyprolis, Blincyto |
| Adaptive Biotechnologies Corporation | $181.79 | 2022-2025 | Clonoseq |
| Gilead Sciences, INC. | $168.34 | 2023-2025 | Trodelvy |
| Servier Pharmaceuticals LLC | $163.89 | 2021-2025 | |
| Genzyme Corporation | $150.01 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $143.67 | 2022-2025 | Calquence, Imfinzi, Lynparza |
| Genentech USA, INC. | $138.62 | 2021-2024 | Lunsumio, Polivy, Columvi |
| Recordati_rare_diseases_inc. | $124.28 | 2025 | Enjaymo, Sylvant |
| Regeneron Healthcare Solutions, INC. | $123.65 | 2022-2025 | Libtayo |
| Jazz Pharmaceuticals INC. | $106.07 | 2021-2025 | |
| Pharmaessentia USA Corporation | $101.70 | 2022-2025 | Besremi |
| Alexion Pharmaceuticals, INC. | $100.73 | 2022-2025 | Ultomiris |
| Sanofi-Aventis U.S. LLC | $99.99 | 2023 | |
| Array Biopharma INC | $93.30 | 2022-2024 | Braftovi, Mektovi, Lorbrena |
| Medtronic, INC. | $78.97 | 2023-2025 | Synchromedii, Osteocool Rf Ablation System, Kyphon Express II Kyphopak Tray |
| Taiho Oncology, INC. | $76.52 | 2023-2025 | |
| Mirati Therapeutics, INC. | $70.73 | 2023 | Krazati |
| Pharmacosmos Therapeutics INC. | $58.67 | 2025 | Monoferric |
| Glaxosmithkline, LLC. | $50.28 | 2023-2024 | Zejula, Jemperli, Ojjaara |
| Syndax Pharmaceuticals, INC. | $44.88 | 2025 | |
| Fennec Pharmaceuticals, INC. | $43.70 | 2025 | Fyarro |
| Sobi, INC | $42.27 | 2023-2025 | |
| Octapharma USA, INC. | $41.34 | 2024-2025 | Octagam Immune Globulin (Human) |
| Blueprint Medicines Corporation | $38.22 | 2022-2023 | Ayvakit |
| Bayer Healthcare Pharmaceuticals INC. | $36.37 | 2022 | |
| Janssen Pharmaceuticals, INC | $35.38 | 2022 | |
| Aveo Pharmaceuticals, INC. | $33.02 | 2022-2025 | |
| Stemline Therapeutics INC. | $31.16 | 2025 | Orserdu |
| Coherus Oncology, INC. | $30.20 | 2021-2024 | |
| Geron Corporation | $23.25 | 2025 | Rytelo |
| Deciphera Pharmaceuticals INC. | $19.47 | 2025 | Qinlock, Romvimza |
| Tolmar Pharmaceuticals, INC. | $19.28 | 2022 | |
| Foundation Medicine, INC. | $17.45 | 2023 | Foundationone Cdx |
| Clovis Oncology, INC. | $16.87 | 2022 | |
| Cti Biopharma Corp. | $16.16 | 2023 | Vonjo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.61 | 2021 | |
| Tactile Systems Technology INC | $14.07 | 2023 | Entre Plus, Flexitouch Plus |
| Tolmar, INC. | $14.05 | 2025 | Eligard, Rubraca |
| Pharmaand Gmbh | $14.05 | 2025 | Rubraca |
| Morphosys, US INC. | $13.53 | 2021 | |
| Amag Pharmaceuticals, INC. | $13.05 | 2022 | |
| Acrotech Biopharma INC. | $12.20 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $11.94 | 2022 | |
| Myriad Genetic Laboratories, INC. | $11.82 | 2022 | |
| Iovance Biotherapeutics, INC. | $11.25 | 2025 | Amtagvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Soe Min Tun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.